311 related articles for article (PubMed ID: 25179432)
1. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
2. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.
Peretz Y; He Z; Shi Y; Yassine-Diab B; Goulet JP; Bordi R; Filali-Mouhim A; Loubert JB; El-Far M; Dupuy FP; Boulassel MR; Tremblay C; Routy JP; Bernard N; Balderas R; Haddad EK; Sékaly RP
PLoS Pathog; 2012; 8(8):e1002840. PubMed ID: 22916009
[TBL] [Abstract][Full Text] [Related]
3. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
[TBL] [Abstract][Full Text] [Related]
4. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
[TBL] [Abstract][Full Text] [Related]
5. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
Front Immunol; 2018; 9():2611. PubMed ID: 30483269
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
[TBL] [Abstract][Full Text] [Related]
8. [CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection].
Wang L; Xu X; Feng G; Zhang X; Wang F
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1559-62. PubMed ID: 25146744
[TBL] [Abstract][Full Text] [Related]
9. Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.
Giustiniani J; Alaoui SS; Marie-Cardine A; Bernard J; Olive D; Bos C; Razafindratsita A; Petropoulou A; de Latour RP; Le Bouteiller P; Bagot M; Socié G; Bensussan A
Curr Mol Med; 2012 Feb; 12(2):188-98. PubMed ID: 22172098
[TBL] [Abstract][Full Text] [Related]
10. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
11. Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers.
Pombo C; Wherry EJ; Gostick E; Price DA; Betts MR
J Infect Dis; 2015 Nov; 212(9):1376-86. PubMed ID: 25883386
[TBL] [Abstract][Full Text] [Related]
12. CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection.
Chibueze CE; Yoshimitsu M; Arima N
Biochem Biophys Res Commun; 2014 Oct; 453(3):379-84. PubMed ID: 25277889
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis of CD160:HVEM Recognition.
Liu W; Garrett SC; Fedorov EV; Ramagopal UA; Garforth SJ; Bonanno JB; Almo SC
Structure; 2019 Aug; 27(8):1286-1295.e4. PubMed ID: 31230945
[TBL] [Abstract][Full Text] [Related]
14. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
[TBL] [Abstract][Full Text] [Related]
15. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
[TBL] [Abstract][Full Text] [Related]
16. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
[TBL] [Abstract][Full Text] [Related]
17. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.
Steinberg MW; Cheung TC; Ware CF
Immunol Rev; 2011 Nov; 244(1):169-87. PubMed ID: 22017438
[TBL] [Abstract][Full Text] [Related]
18. CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.
Viganò S; Banga R; Bellanger F; Pellaton C; Farina A; Comte D; Harari A; Perreau M
PLoS Pathog; 2014 Sep; 10(9):e1004380. PubMed ID: 25255144
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.
Giustiniani J; Bensussan A; Marie-Cardine A
J Immunol; 2009 Jan; 182(1):63-71. PubMed ID: 19109136
[TBL] [Abstract][Full Text] [Related]
20. CD160 expression on CD8
Liu S; Zhang W; Liu K; Wang Y
Cancer Immunol Immunother; 2020 May; 69(5):789-797. PubMed ID: 32055919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
